Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
The Danish biotechnology company on Thursday reported revenue of 9.1 billion Danish kroner for the six months ended June 30, a massive increase from 49 million Danish kroner in the same period a year earlier.
Its operating result swung to a profit of 8.1 billion Danish kroner from a loss of 524 million Danish kroner, according to its half-year report.
The financial transformation was driven by a collaboration and license agreement with Roche that closed in May and included an upfront payment of $1.65 billion.
Under the deal, the companies will co-develop and co-commercialize petrelintide, sharing profits and losses in the U.S. and Europe, Zealand said.
"Our organizational strength and very solid financial position empower us to unlock the full value potential of petrelintide and to accelerate investments in the next wave of innovation," said CEO Adam Steensberg.
The company also highlighted progress in its broader obesity pipeline, noting positive 28-week trial results for another candidate, dapiglutide, which showed an 11.4% placebo-adjusted weight loss.
Zealand said the petrelintide program is advancing at "full speed," with Phase 2 trials progressing and Roche beginning construction on a new manufacturing facility for obesity medicines.
More from this issuer
Related coverage
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.